
    
      Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic
      Arthritis to a target (disease activity score <2.6), or as per their routine care. The aim of
      this study is to determine whether treating to a target results in greater disease
      improvement than treating patients using routine care.
    
  